INmune Bio Inc expected to post a loss of 40 cents a share - Earnings Preview

Inmune Bio

28/07/2023 22:27

* INmune Bio Inc  INMB.OQ   INMB.O  is expected to show a
fall in
quarterly revenue when it reports  results on August 1
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for INmune Bio Inc is
for a
loss of 40 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for INmune Bio
Inc is
$16​, above​ its last closing price of $8.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.02       -0.02      -0.36     Missed  -1,700
 Dec. 31 2023  -0.47       -0.48      -0.32     Beat    34
 Sep. 30 2022  -0.53       -0.52      -0.43     Beat    18.1​
 Jun. 30 2022  -0.50       -0.50      -0.38     Beat    24.8
 ​​Mar.        -0.68       -0.64      -0.39     Beat    39.1
 31 2022                                                
 Dec. 31 2021  -0.56       -0.58      -0.55     Beat    4.6​
 Sep. 30 2021  -0.37       -0.35      -0.55     Missed  -54.9
 Jun. 30 2021  -0.34       -0.34      -0.44     Missed  -29.4
 This summary was machine generated July 28 at 21:27 GMT.  All
figures in US dollars  unless otherwise stated